RSLS vs. NMRD, DYNT, QNRX, OSAP, INVO, TNON, BJDX, GMVDF, IONM, and SINT
Should you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include Nemaura Medical (NMRD), Dynatronics (DYNT), Quoin Pharmaceuticals (QNRX), ProSomnus (OSAP), INVO Bioscience (INVO), Tenon Medical (TNON), Bluejay Diagnostics (BJDX), G Medical Innovations (GMVDF), Assure (IONM), and Sintx Technologies (SINT). These companies are all part of the "surgical & medical instruments" industry.
Nemaura Medical (NASDAQ:NMRD) and ReShape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
ReShape Lifesciences received 394 more outperform votes than Nemaura Medical when rated by MarketBeat users. Likewise, 66.22% of users gave ReShape Lifesciences an outperform vote while only 57.14% of users gave Nemaura Medical an outperform vote.
Nemaura Medical has a net margin of 0.00% compared to Nemaura Medical's net margin of -131.22%. ReShape Lifesciences' return on equity of 0.00% beat Nemaura Medical's return on equity.
Nemaura Medical presently has a consensus target price of $2.50, suggesting a potential upside of 7,475.76%. Given ReShape Lifesciences' higher possible upside, analysts clearly believe Nemaura Medical is more favorable than ReShape Lifesciences.
4.4% of Nemaura Medical shares are owned by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are owned by institutional investors. 41.6% of Nemaura Medical shares are owned by insiders. Comparatively, 0.1% of ReShape Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Nemaura Medical has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
ReShape Lifesciences has higher revenue and earnings than Nemaura Medical.
In the previous week, ReShape Lifesciences' average media sentiment score of 0.00 equaled Nemaura Medical'saverage media sentiment score.
Summary
ReShape Lifesciences beats Nemaura Medical on 7 of the 13 factors compared between the two stocks.
Get ReShape Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ReShape Lifesciences Competitors List
Related Companies and Tools
